虽然CorMedix的短期利息上, 但积极的收益和分析师评级使其股票接近9.85美元. CorMedix's short interest rose, yet positive earnings and analyst ratings buoyed its stock near $9.85.

生物制药公司CorMedix Inc.在11月份的短期利息增长了8.9%,达到684万股. CorMedix Inc., a biopharmaceutical company, saw its short interest increase by 8.9% to 6.84 million shares in November. 尽管如此,最近的收入超过了预期,公司报告的EPS和收入都比预期的要好。 Despite this, recent earnings surpassed expectations, with the company reporting better-than-expected EPS and revenue. Nedham & Company LLC和Rodman & Renshaw等分析家给予正面评价,目标价格高达18美元。 Analysts like Needham & Company LLC and Rodman & Renshaw have given positive ratings, with target prices up to $18.00. 然而,股票保持稳定,为9.85美元,反映了投资者的复杂情绪。 The stock, however, remained stable at $9.85, reflecting a complex investor sentiment.